Melinta Therapeutics Publishes Complete Results from Phase 3 TANGO I Study of VABOMERE™ in Patients with cUTI

  • VABOMERE demonstrated a greater numerical overall success rate vs piperacillin-tazobactam
  • VABOMERE safety profile comparable to piperacillin-tazobactam

Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, announced today that results from the Phase 3 TANGO I study of VABOMERE™ (meropenem and vaborbactam) for injection were published in the Journal of the American Medical Association (JAMA). VABOMERE was approved by the U.S. Food and Drug Administration (FDA) in August 2017 for the treatment of adult patients with complicated urinary tract infections (cUTI), including pyelonephritis, caused by designated susceptible Enterobacteriaceae: Escherichia coli, Klebsiella pneumoniae and Enterobacter cloacae species complex. The Targeting Antibiotic Non-susceptible Gram-negative Organisms (TANGO I) trial was the pivotal Phase 3 study that compared the efficacy and safety of VABOMERE to piperacillin-tazobactam in the treatment of patients with cUTI and acute pyelonephritis (AP).